CA2686165A1 - Compositions comprising mir34 therapeutic agents for treating cancer - Google Patents

Compositions comprising mir34 therapeutic agents for treating cancer Download PDF

Info

Publication number
CA2686165A1
CA2686165A1 CA 2686165 CA2686165A CA2686165A1 CA 2686165 A1 CA2686165 A1 CA 2686165A1 CA 2686165 CA2686165 CA 2686165 CA 2686165 A CA2686165 A CA 2686165A CA 2686165 A1 CA2686165 A1 CA 2686165A1
Authority
CA
Canada
Prior art keywords
seq
nucleic acid
strand
nucleotide
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2686165
Other languages
English (en)
French (fr)
Inventor
Michele A. Cleary
Aimee L. Jackson
Peter S. Linsley
Julja Burchard
Lee P. Lim
Jill F. Magnus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Inpharmatics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2686165A1 publication Critical patent/CA2686165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2686165 2007-05-03 2008-05-05 Compositions comprising mir34 therapeutic agents for treating cancer Abandoned CA2686165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92762107P 2007-05-03 2007-05-03
US60/927,621 2007-05-03
PCT/US2008/062689 WO2008137867A2 (en) 2007-05-03 2008-05-05 Compositions comprising mir34 therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
CA2686165A1 true CA2686165A1 (en) 2008-11-13

Family

ID=39944228

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2686165 Abandoned CA2686165A1 (en) 2007-05-03 2008-05-05 Compositions comprising mir34 therapeutic agents for treating cancer

Country Status (6)

Country Link
US (2) US8378088B2 (enExample)
EP (1) EP2152722B1 (enExample)
JP (1) JP2010525826A (enExample)
AU (1) AU2008247427A1 (enExample)
CA (1) CA2686165A1 (enExample)
WO (2) WO2008137862A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111304327A (zh) * 2020-02-24 2020-06-19 宋程 人grpel2基因的用途及相关产品

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290068A3 (en) 2004-05-28 2012-01-04 Asuragen, Inc. Methods and compositions involving microRNA
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
AU2008247427A1 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising miR34 therapeutic agents for treating cancer
CN101801419A (zh) * 2007-06-08 2010-08-11 米尔纳疗法公司 作为治疗干预的靶标的miR-34调控的基因和路径
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US8841268B2 (en) * 2008-05-07 2014-09-23 Sapporo Medical University Method and kit for detection of cancer, and therapeutic agent for cancer
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
EP2191834A1 (en) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
LU91545B1 (en) 2009-03-27 2010-09-28 Univ Luxembourg Mirna as a prognostic diagnostic biomarker and therapeutic agent for breast cancer and other human associated pathologies
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
FR2948687B1 (fr) 2009-07-29 2015-09-04 Centre Nat Rech Scient Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
EP2476758A4 (en) * 2009-09-07 2013-04-03 Yoshiki Murakami METHOD FOR PREDICTING THE THERAPEUTIC EFFECT ON CHRONIC HEPATITIS C
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
WO2011133874A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Multicistronic expression constructs
US20130149320A1 (en) * 2010-05-31 2013-06-13 Centre National De La Recherche Scientifique Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
CN102031309A (zh) * 2010-11-30 2011-04-27 华东师范大学 miRNA-34c化合物作为脑胶质瘤标志物的应用
EP2670850B1 (en) * 2011-02-03 2016-10-26 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
US9222085B2 (en) 2011-02-03 2015-12-29 Mirna Therapeutics, Inc. Synthetic mimics of MIR-124
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20130028956A1 (en) 2011-07-29 2013-01-31 Andre Fischer Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
EP2785872A4 (en) * 2011-12-01 2015-12-09 Univ Ohio State MATERIALS AND METHODS RELATED TO NSAID CHEMOPRVENTION IN COLORECTAL CANCER
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
EP2857513A4 (en) 2012-05-26 2016-05-25 Bonac Corp Single-stranded nucleic acid molecule controlling the expression of a gene transporter
SG10201912895PA (en) * 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
CN105324119A (zh) * 2013-06-16 2016-02-10 国立大学法人东京医科齿科大学 具有外显子跳跃效应的双链反义核酸
JP6486836B2 (ja) 2013-12-26 2019-03-20 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
RU2697094C2 (ru) 2013-12-27 2019-08-12 Бонак Корпорейшн ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
AU2015368293B2 (en) 2014-12-27 2021-07-22 Bonac Corporation Naturally occuring miRNA for controlling gene expression, and use of same
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
HK1244031A1 (en) 2015-03-27 2018-07-27 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
WO2016172008A1 (en) 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
EP3364996B1 (en) * 2015-10-22 2021-08-25 University of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
WO2017152182A1 (en) * 2016-03-04 2017-09-08 Rhode Island Hospital Targeting microrna for cancer treatment
EP3216869B1 (en) 2016-03-09 2019-09-18 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of leukemia
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
JP6651061B2 (ja) 2017-11-09 2020-02-19 国立大学法人広島大学 ｍｉＲＮＡを含むがん治療用医薬組成物
CN107699565B (zh) * 2017-11-24 2020-05-22 苏州大学 微小rna及其在制备抗肿瘤药物中的应用
CN110791566B (zh) * 2019-10-29 2023-06-27 徐州市中心医院 人shcbp1基因的用途及相关产品
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN114010523B (zh) * 2021-11-05 2024-04-12 天津穗纳生物医药科技有限公司 皮肤抗衰剂及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177568A1 (en) 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2005018534A2 (en) 2003-05-16 2005-03-03 Rosetta Inpharmatics, Llc Methods and compositions for rna interference
US6882555B2 (en) 2003-06-18 2005-04-19 Lattice Semiconductor Corporation Bi-directional buffering for memory data lines
WO2005031002A2 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
EP1784501B1 (en) 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
EP2290068A3 (en) * 2004-05-28 2012-01-04 Asuragen, Inc. Methods and compositions involving microRNA
WO2007056829A1 (en) 2005-11-21 2007-05-24 Johnson & Johnson Research Pty Limited Multitargeting interfering rnas having two active strands and methods for their design and use
US7893975B2 (en) * 2006-10-13 2011-02-22 Apple Inc. System and method for processing images using predetermined tone reproduction curves
EP2087301B1 (en) * 2006-11-07 2018-11-14 Tiax LLC dehumidification system and method for dehumidification
EP2111408A4 (en) 2007-01-17 2010-02-03 Univ Johns Hopkins COMPOSITIONS AND METHODS OF microRNA FOR THE TREATMENT OF NEOPLASIA
AU2008220438A1 (en) 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
AU2008247427A1 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising miR34 therapeutic agents for treating cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111304327A (zh) * 2020-02-24 2020-06-19 宋程 人grpel2基因的用途及相关产品
CN111304327B (zh) * 2020-02-24 2024-04-19 宋程 人grpel2基因的用途及相关产品

Also Published As

Publication number Publication date
US20100227909A1 (en) 2010-09-09
WO2008137867A3 (en) 2009-04-16
EP2152722A4 (en) 2011-12-28
AU2008247427A1 (en) 2008-11-13
JP2010525826A (ja) 2010-07-29
EP2152722B1 (en) 2016-04-27
WO2008137862A3 (en) 2009-02-19
WO2008137862A2 (en) 2008-11-13
US20110105583A1 (en) 2011-05-05
WO2008137867A2 (en) 2008-11-13
US8399248B2 (en) 2013-03-19
EP2152722A2 (en) 2010-02-17
US8378088B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
EP2152722B1 (en) Compositions comprising mir34 therapeutic agents for treating cancer
Krützfeldt et al. Silencing of microRNAs in vivo with ‘antagomirs’
Kushlinskii et al. Molecular mechanisms and microRNAs in osteosarcoma pathogenesis
WO2009131887A2 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
US8053186B2 (en) Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
US20110118337A1 (en) Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
US20090136957A1 (en) Methods and compositions for regulating cell cycle progression via the miR-106B family
US20110052502A1 (en) MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
US20130273079A1 (en) Ultraconserved Regions Encoding ncRNAs
US20070299030A1 (en) MicroRNA biomarkers for human breast and lung cancer
US9056135B2 (en) MicroRNA biomarkers for human breast and lung cancer
WO2008088858A2 (en) Compositions and methods featuring micronas for treating neoplasia
CN101376910B (zh) 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
WO2011111715A1 (ja) 細胞周期を制御する核酸
JP4851940B2 (ja) がんまたは糖尿病治療のための医薬組成物
KR102293777B1 (ko) 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
CN113924127A (zh) 在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络
AU2013224690A1 (en) Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
Chen MicroRNA-193b functions as a tumor suppressor in malignant melanoma
Pedersen MicroRNA 21’s effect on apoptosis and insulin secretion in insulin secreting β-cell lines.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130506